The Survey Research Facility (SRF) was founded in April 1991 and has been a Cancer Center Shared Resource since 2003. Its purpose is to facilitate the conduct of high quality science through the provision of excellent consultation and service delivery for all aspects of survey design and conduct for Mayo Clinic Cancer Center (MCCC) investigators. The SRF strives for excellence by providing high quality and efficient service delivery by deploying """"""""state of the science"""""""" methods in the areas of instrument development, sampling, mailing, telephoning, response tracking, instrument processing, and data file preparation. The SRF is the only Mayo Clinic facility offering this comprehensive set of services. The SRF has conducted over 1,500 survey-based studies since its inception. During the current grant period alone (2004-07), the SRF conducted 658 separate survey studies. Overall, approximately 16% of the studies conducted by the SRF are cancer-related, with the vast majority (approximately 90%) of those done in collaboration with MCCC members. For MCCC investigators, this resource has and will continue to provide expert consultation and support for the conduct of survey research relevant to their research endeavors. To date, these have been aimed at risk factor assessment, obtaining outcomes following diagnosis or treatment, recruitment for clinical trials, assessing attitudes and behaviors related to cancer screening, assessing the acceptability of cancer screening methods, determination of family trees for genetic studies, assessing satisfaction with cancer related treatment and associated health care encounters, assessing informational needs for cancer patients, assessment of the willingness to help others to stop smoking (cancer prevention), psychological scale development pertinent to intervening on adolescents who use tobacco, and quality of life assessment in cancer patients. The demand for SRF services by MCCC investigators continues to remain high. The SRF is working to expand its range of services, especially with respect to qualitative analysis and psychometric expertise related to patient-reported outcomes and quality of life assessment. The SRF will also expand the capabilities of its project and respondent tracking systems and implement processes and procedures to assure compliance with the new HIPAA regulations as they pertain to survey work.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-38
Application #
8382245
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$124,388
Indirect Cost
$69,531
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications